Advertisement

Liver Diseases pp 143-151 | Cite as

Autoimmune Hepatitis

  • Christos Liaskos
  • George Efthymiou
  • Dimitrios P. BogdanosEmail author
Chapter

Abstract

Autoimmune hepatitis (AIH) is a relatively rare autoimmune liver disease of unknown aetiology. The disease is characterized by immune-mediated destruction of the hepatocytes and progressive inflammation and subsequent liver fibrosis leading to organ’s failure, if the disease is left untreated. Genetic, epigenetic and immunological factors are considered important for the development of the disease.

Keywords

Antibody Autoantibody Autoantigen Autoimmunity Clinician Disease Hepatitis Liver Autoimmune liver disease Corticosteroids 

Abbreviations

AIH

Autoimmune hepatitis

AMA

Anti-mitochondrial antibody

LC1

Liver cytosol type 1

LKM-1

Liver kidney microsomal type 1

p-ANCA

Perinuclear antineutrophil cytoplasmic antibodies

SMA

Smooth muscle antibody

References

  1. 1.
    Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31(5):929–38.CrossRefGoogle Scholar
  2. 2.
    Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76.CrossRefGoogle Scholar
  3. 3.
    Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol. 2004;41(4):677–83.CrossRefGoogle Scholar
  4. 4.
    Bogdanos DP, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol. 2008;14(21):3374–87.CrossRefGoogle Scholar
  5. 5.
    Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med. 2001;1(3):379–89.CrossRefGoogle Scholar
  6. 6.
    Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology. 2006;130(3):868–82.CrossRefGoogle Scholar
  7. 7.
    Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol. 2009;31(3):421–35.CrossRefGoogle Scholar
  8. 8.
    Hardtke-Wolenski M, Jaeckel E. Mouse models for experimental autoimmune hepatitis: limits and chances. Dig Dis. 2010;28(1):70–9.CrossRefGoogle Scholar
  9. 9.
    Ehser J, Holdener M, Christen S, Bayer M, Pfeilschifter JM, Hintermann E, et al. Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. J Autoimmun. 2013;42:39–49.CrossRefGoogle Scholar
  10. 10.
    Bogdanos DP, Lenzi M, Okamoto M, Rigopoulou EI, Muratori P, Ma Y, et al. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA B51. Int J Immunopathol Pharmacol. 2004;17(1):83–92.CrossRefGoogle Scholar
  11. 11.
    Smyk DS, Mavropoulos A, Mieli-Vergani G, Vergani D, Lenzi M, Bogdanos DP. The role of invariant NKT in autoimmune liver disease: can vitamin D act as an immunomodulator? Can J Gastroenterol Hepatol. 2018;2018:8197937.CrossRefGoogle Scholar
  12. 12.
    de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147(2):443–52 e5.CrossRefGoogle Scholar
  13. 13.
    van Gerven NM, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245–54.CrossRefGoogle Scholar
  14. 14.
    Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology. 1997;25(3):541–7.CrossRefGoogle Scholar
  15. 15.
    Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998;33(1):99–103.CrossRefGoogle Scholar
  16. 16.
    Feld JJ, Heathcote EJ. Epidemiology of autoimmune liver disease. J Gastroenterol Hepatol. 2003;18(10):1118–28.CrossRefGoogle Scholar
  17. 17.
    Werner M, Prytz H, Ohlsson B, Almer S, Bjornsson E, Bergquist A, et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol. 2008;43(10):1232–40.CrossRefGoogle Scholar
  18. 18.
    Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54–66.CrossRefGoogle Scholar
  19. 19.
    Czaja AJ, Carpenter HA. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34(4 Pt 1):659–65.CrossRefGoogle Scholar
  20. 20.
    Bogdanos DP, Mieli-Vergani G, Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis. 2009;29(3):241–53.CrossRefGoogle Scholar
  21. 21.
    Radzimski C, Probst C, Teegen B, Rentzsch K, Blocker IM, Dahnrich C, et al. Development of a recombinant cell-based indirect immunofluorescence assay for the determination of autoantibodies against soluble liver antigen in autoimmune hepatitis. Clin Dev Immunol. 2013;2013:572815.CrossRefGoogle Scholar
  22. 22.
    European Association for the Study of the L. EASL Clinical Practice Guidelines: autoimmune hepatitis. J Hepatol. 2015;63(4):971–1004.CrossRefGoogle Scholar
  23. 23.
    Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.CrossRefGoogle Scholar
  24. 24.
    van Gerven NM, Verwer BJ, Witte BI, van Hoek B, Coenraad MJ, van Erpecum KJ, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol. 2013;58(1):141–7.CrossRefGoogle Scholar
  25. 25.
    Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl. 2013;19(10):1065–77.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Christos Liaskos
    • 1
  • George Efthymiou
    • 1
  • Dimitrios P. Bogdanos
    • 1
    Email author
  1. 1.Division of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health SciencesUniversity of ThessalyLarissaGreece

Personalised recommendations